Proteomic investigating the cooperative lethal effect of EGFR and MDM2 inhibitors on ovarian carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Archives of biochemistry and biophysics"
DOI: 10.1016/j.abb.2018.04.004
Abstract: With the concept of precision medicine, combining multiple molecular-targeting therapies has brought new approaches to current cancer treatments. Malfunction of the tumor suppressor protein, p53 is a universal hallmark in human cancers. Under normal conditions,… read more here.
Keywords: egfr; mdm2 inhibitors; mdm2; inhibition ... See more keywords
Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22168784
Abstract: As the most common gene mutation found in cancers, p53 mutations are detected in up to 96% of high-grade serous ovarian carcinoma (HGSOC). Meanwhile, mutant p53 overexpression is known to drive oncogenic phenotypes in cancer… read more here.
Keywords: inhibition; egfr mdm2; function; p53 ... See more keywords